On representing the prognostic value of continuous gene expression biomarkers with the restricted mean survival curve

Oncotarget

Volumn 6, Issue 34, 2015, Pages 36308-36318

  Eng, Kevin H ^a   Schiller, Emily ^a   Morrell, Kayla ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Dichotomization; Model diagnostics; Prognostic marker; Restricted mean survival; Survival analysis

Indexed keywords

PACLITAXEL; PLATINUM COMPLEX; TOPOTECAN; TUMOR MARKER;

ADJUVANT THERAPY; ALGORITHM; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; GENE EXPRESSION; GENETIC SCREENING; HUMAN; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; ONCOLOGICAL PARAMETERS; OUTCOME ASSESSMENT; OVARY CANCER; PREDICTIVE VALUE; RESTRICTED MEAN SURVIVAL; RESTRICTED MEAN SURVIVAL CURVE; RISK ASSESSMENT; SCORING SYSTEM; TREATMENT RESPONSE; VALIDATION STUDY; BIOSYNTHESIS; FEMALE; GENETICS; KAPLAN MEIER METHOD; METABOLISM; OVARY TUMOR; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; STATISTICAL MODEL;

BIOMARKERS, TUMOR; FEMALE; GENE EXPRESSION; HUMANS; KAPLAN-MEIER ESTIMATE; LINEAR MODELS; OVARIAN NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS;

EID: 84946865849     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.6121     Document Type: Article

References (20)

1. The Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011; 474:609-615.
2. Altman, D. G., Lausen, B., Sauerbrei, W., and Schumacher, M. Dangers of using optimal cutpoints in the evaluation of prognostic factors. Journal of the National Cancer Institute. 1994; 86: 829-835.
3. Hilsenbeck, S. G., Clark, G. M., and McGuire, W. L. Why do so many prognostic factors fail to pan out? Breast Cancer Research and Treatment. 1992; 22: 197-206.
4. Contal, C. and O'Quigley, J. An application of changepoint methods in studying the effect of age on survival in breast cancer.Computational Statistics & Data Analysis. 1999; 30: 253-70.
5. Klein, J. and Moeschberger, M. Survival analysis: statistical methods for censored and truncated data. Springer-Verlag, NY, NY.
6. Mazumdar, M. and Glassman, J. R. Categorizing a prognostic variable: review of methods, code for easyimplementation and applications to decision-making about cancer treatments. Statistics in Medicine. 2000; 19:113-132.
7. Royston, P., Sauerbrei, W., and Altman, D. G. Modeling the effects of continuous risk factors. Journal of Clinical Epidemiology. 2000; 53: 219-220.
8. Motakis, E., Ivshina, A., and Kuznetsov, V. Data-driven approach to predict survival of cancer patients. Engineering in Medicine and Biology Magazine. IEEE 2009; 28:58-66.
9. Gyorffy, B., Surowiak, P., Budczies, J., and Lanczky, A. Online survival analysis software to assess the prognostic valueof biomarkers using transcriptomic data in non-smallcell lungcancer. PLoS One. 2013; 8: e82241.
10. Cox, D. Regression models and life-tables. Journal of the Royal Statistical Society. Series B. 1972; 34, 187-220.
11. Verhaak, R. G., Tamayo, P., Yang, J.-Y., Hubbard, D., Zhang, H., Creighton, C. J., Fereday, S., Lawrence, M., Carter, S. L., Mermel, C. H., et al. Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. The Journal of Clinical Investigation 2013; 123:517-525.
12. Gu, C. Hazard Rate Estimation. In: Smoothing Spline ANOVA Models. pp211-230. 2002. Springer.
13. Therneau, T. M. (2015). A Package for Survival Analysis in S. version 2.38.
14. Eng, K. H., Wang, S., Bradley, W. H., Rader, J. S., and Kendziorski, C. Pathway index models for construction of patient-specific risk profiles. Statistics in Medicine. 2013; 32: 1524-1535.
15. Janes, H., Pepe, M. S., Bossuyt, P. M., and Barlow, W. E. Measuring the performance of markers for guiding treatmentdecisions. Annals of Internal Medicine. 2011; 154, 253-259.
16. Mazumdar, M., Smith, A., and Bacik, J. Methods forcategorizing a prognostic variable in a multivariable setting. Statistics in Medicine. 2003; 22, 559-571.
17. Breslow, N. Covariance analysis of censored survival data. Biometrics. 1974; 30, 89-99.
18. Link, C. L. Confidence intervals for the survival function using cox's proportional-hazard model with covariates. Biometrics. 1984; 40, 601-609.
19. Hosmer, D., Lemeshow, S., and May, S. Applied Survival Analysis: Regression Modeling of Time to Event Data. 2011. Wiley.
20. Royston, P. and Parmar, M. K. Restricted mean survival time: an alternative to the hazard ratio for the design and analysisof randomized trials with a time-to-event outcome. BMC Medical Research Methodology. 2013; 13, 152.